Atomic AI, Inc. is a well-funded, early-stage biotech company transforming the rational design of molecules and medicines through the cutting-edge fusion of artificial intelligence and structural biology. Atomic’s unique R&D platform, based on research featured on the cover of Science (doi.org/10.1126/science.abe5650), provides new strategies to treat or cure previously undruggable diseases by targeting RNA structure. We are an interdisciplinary team working across computational and experimental biology and believe that our strongest asset is our people.


Join TechBio Companies Driving Patient Impact